Last reviewed · How we verify
Guafenesin tablets
Guaifenesin reduces mucus viscosity and promotes clearance of respiratory secretions by increasing hydration of mucus in the airways.
Guaifenesin reduces mucus viscosity and promotes clearance of respiratory secretions by increasing hydration of mucus in the airways. Used for Productive cough due to common cold, flu, or other respiratory conditions.
At a glance
| Generic name | Guafenesin tablets |
|---|---|
| Also known as | Mucinex® |
| Sponsor | American Health Research |
| Drug class | Expectorant |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Guaifenesin is an expectorant that works by thinning mucus secretions in the respiratory tract, making them less viscous and easier to expectorate. It is thought to act by increasing the water content of respiratory secretions, thereby reducing mucus thickness and facilitating clearance through coughing. This mechanism helps relieve chest congestion associated with colds, flu, and other respiratory conditions.
Approved indications
- Productive cough due to common cold, flu, or other respiratory conditions
Common side effects
- Nausea
- Vomiting
- Dizziness
- Headache
- Rash
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Guafenesin tablets CI brief — competitive landscape report
- Guafenesin tablets updates RSS · CI watch RSS
- American Health Research portfolio CI